Peer-reviewed veterinary case report
Canine intranasal tumor treatment with surgery and acridine orange
By Maruo, Takuya et al.·Published in The Canadian veterinary journal = La revue veterinaire canadienne·2015·Veterinary Teaching Hospital, United States·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Intraoperative acridine orange photodynamic therapy and cribriform electron-beam irradiation for canine intranasal tumors: A pilot study.
- Species:
- dog
Plain-English summary
A group of 6 dogs with intranasal tumors underwent surgery to remove part of the tumor, followed by a special light therapy (acridine orange photodynamic therapy) and radiation treatment. The dogs had varying stages of cancer, and after treatment, they lived a median of 13 months, with some experiencing a recurrence of the tumor after 4 to 7 months. Most side effects were mild, including some nasal irritation. This combination treatment may help control tumor growth in dogs with certain types of nasal tumors.
People also search for: dog nasal tumor treatment · canine photodynamic therapy · intranasal cancer in dogs · dog radiation therapy side effects
Abstract
Untreated canine intranasal tumors carry a poor prognosis. We retrospectively evaluated the efficacy of marginal tumor resection in combination with intraoperative acridine orange (AO) photodynamic therapy (PDT) and 1 fraction of 5 Gy megavoltage irradiation for canine intranasal malignant tumors. When cribriform plate invasion or turbinate destruction around the cribriform plate was present, an additional fraction of 20 Gy was delivered with an electron beam during surgery. The study included 6 dogs, 2 of which were classified as stage I, 1 as stage II, and 3 as stage IV. The median local disease-free survival time and overall survival after the treatment were 8.5 and 13 months, respectively. Recurrence was noted in 2 of the 6 dogs after 4 and 7 months. Adverse events were mild (subcutaneous emphysema in 1 case, and rhinitis in 3 cases). Combination AO therapy may increase the tumor control time of dogs with marginally resectable intranasal malignant tumors.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/26663917/